Device Trial Radar · NCT06056154
Safety and Efficacy of the Hydrophobic Intraocular Lens Asqelio Monofocal With Biaspheric Design
Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 17, 2024
Primary completion
May 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- AST Products, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to learn about the Asqelio monofocal intraocular lens (IOL) model QLIO130C in patients undergoing cataract surgery. The aim of the study is to evaluate the lens implementation safety and efficacy after at least 24 months.
Conditions
- Cataract
- Pseudophakia
Interventions
LIO ASQELIO TM monofocal QLIO130CDevice
Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Posterior capsular opacityTime frame: 24 months after IOL implantation
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Oftalmología Vistahermosa SL
Alicante, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.